Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, has launched a new prefilled syringe capability in the US through its affiliate, Hikma Pharmaceuticals USA Inc. The first Hikma medicine available in prefilled syringe form is Heparin Sodium Injection, USP, 5000 Units/mL.
“Medical professionals are always in need of tools that help them improve the speed, safety and accuracy of patient care and that is why Hikma is excited to launch our prefilled syringe capability,” said Dan Motto, Hikma’s EVP of Commercial & Business Development, US Injectables. “Our Heparin Sodium Injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of US medical professionals and their patients.”
“Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines” said Riad Mishlawi, President, Hikma Injectables. “We have made significant investments in our US manufacturing capabilities to bring this new prefilled syringe capability to market, and Heparin is the first of many important medicines we will deliver in this form.”
Heparin Sodium Injection is indicated for:
- Prophylaxis and treatment of venous thrombosis and pulmonary embolism;
- Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or
- who, for other reasons, are at risk of developing thromboembolic disease;
Atrial fibrillation with embolization; - Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation);
- Prevention of clotting in arterial and cardiac surgery;
- Prophylaxis and treatment of peripheral arterial embolism;
- Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures
Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.
